Business Context and Reporting Period
Company: Inotiv, Inc. (NOTV)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended March 31, 2026
Business Overview: Inotiv is a contract research organization (CRO) providing nonclinical drug discovery, safety assessment, and research models (including non-human primates) to pharmaceutical, medical device, and academic clients. Operations are divided into two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2026 |
Three Months Ended Mar 31, 2025 |
Six Months Ended Mar 31, 2026 |
Six Months Ended Mar 31, 2025 |
|---|---|---|---|---|
| Total Revenue | $117,652 | $124,323 | $238,531 | $244,199 |
| Operating Loss | $(19,309) | $(2,938) | $(35,639) | $(18,445) |
| Net Loss | $(32,467) | $(14,866) | $(60,845) | $(42,496) |
| Loss Per Share (Basic/Diluted) | $(0.94) | $(0.44) | $(1.76) | $(1.39) |
| Cash and Cash Equivalents | $15,180 | $21,741 (Sep 30, 2025) | $15,180 | $21,432 (Sep 30, 2024) |
| Net Cash Used in Operating Activities | N/A | N/A | $(6,503) | $(17,312) |
| Total Debt (Current Portion) | $410,422 | $402,123 (Sep 30, 2025) | $410,422 | $402,123 (Sep 30, 2025) |
| Revolving Credit Facility Outstanding | $13,000 | $3,000 (Sep 30, 2025) | $13,000 | $3,000 (Sep 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 5.4% ($6.7M) for the quarter and 2.3% ($5.7M) for the six months compared to the prior year. This was driven by a 10.7% decline in RMS revenue due to lower non-human primate (NHP) volumes, partially offset by a 3.9% increase in DSA revenue.
- Widening Losses: Net loss increased significantly, rising from $14.9M to $32.5M for the quarter and from $42.5M to $60.8M for the six months. This deterioration was caused by lower RMS margins, increased operating expenses (including cybersecurity incident costs and legal fees), and higher interest expense.
- Segment Performance: The DSA segment remained profitable with operating income of $1.0M for the quarter. Conversely, the RMS segment swung from an operating income of $11.4M in the prior year to an operating loss of $1.9M, primarily due to revenue declines and the absence of a one-time settlement gain received in the prior period.
- Cash Flow Improvement: Net cash used in operating activities improved to $6.5M for the six months ended March 31, 2026, compared to $17.3M in the prior year period, driven by reductions in trade receivables and inventory.
Guidance, Outlook, Risks, and Contingencies
Going Concern and Liquidity
The Company has disclosed substantial doubt about its ability to continue as a going concern. Management forecasts noncompliance with financial covenants under its Credit Agreement for the remainder of fiscal 2026. While lenders granted waivers for the period ended March 31, 2026, the Company believes existing cash and operating cash flows will be insufficient to fund operations and satisfy obligations for the next 12 months without a strategic transaction (recapitalization, refinancing, or restructuring).
Debt and Covenant Status
- Convertible Notes Default Risk: An interest payment of approximately $2.1M on Convertible Senior Notes was due April 15, 2026. As of the filing date, this payment had not been made. The grace period expires May 15, 2026. Failure to pay will trigger an event of default, potentially accelerating all debt.
- Debt Maturity: Significant debt obligations, including Term Loans, Delayed Draw Term Loans, and Second Lien Notes, mature within the next 12 months.
- Credit Agreement: The Company is subject to strict liquidity covenants (minimum $30M liquidity) and leverage ratios. Recent waivers were obtained, but future compliance is uncertain.
Legal and Regulatory Contingencies
- DOJ Resolution: The Company is subject to a Resolution and Plea Agreement with the DOJ regarding a former canine breeding facility, requiring fines totaling $22M and a five-year compliance monitorship.
- Litigation Settlements: Securities class action and derivative lawsuits were settled in late 2025/early 2026. Payments totaling $8.75M (class action) and $2.25M (attorneys' fees) were made, largely funded by insurance.
- Cybersecurity: Costs related to a 2025 cybersecurity incident impacted operating expenses. Privacy class actions were dismissed in federal court but refiled in state court.
Market Risks
- Nasdaq Delisting: The Company received notice of non-compliance with the Minimum Bid Price Rule ($1.00/share) on December 31, 2025. It has until June 29, 2026, to regain compliance or risk delisting.
- Tariffs: Imported NHPs are subject to tariffs (15-20% in Q1/Q2 2026), negatively impacting cash flows. A potential refund of previously paid tariffs is uncertain.
Investor Verification Checklist
- Interest Payment Status: Verify if the $2.1M Convertible Note interest payment due April 15, 2026, has been made to avoid an immediate event of default.
- Debt Restructuring Progress: Monitor announcements regarding the exploration of recapitalization, refinancing, or restructuring transactions to address the going concern warning.
- Covenant Compliance: Track weekly liquidity reports and covenant waivers to ensure the Company avoids acceleration of its $410M+ debt obligations.
- Nasdaq Compliance: Watch for stock price movements or reverse split proposals to address the Minimum Bid Price deficiency before the June 29, 2026 deadline.
- Segment Mix: Assess the sustainability of DSA growth versus the continued decline in RMS volumes and margins.